|
|
|
| Effect of mifepristone combined with gestrinone for treating the patients with adenomyosis and its influence on the levels of prostaglandin f 2a and βendorphins and the uterine recovery of these patients |
| Beijing Sixth Hospital, Beijing, 100007 |
|
|
|
|
Abstract To study the effect of mifepristone combined with gestrinone for treating the patients with adenomyosis, and to analyze its influence on the levels of prostaglandin f 2a (PGF 2a) and βendorphins (β EP), and the uterine recovery of these patients. Methods: 105 patients with adenomyosis treated in hospital were selected and were divided into experimental group (n=53) and control group (n=52) by random number table method from January 2020 to January 2022. The patients in the control group were treated with gestational trienone, and the patients in the experimental group were treated with gestational trienone combined with mifepristone. The clinical efficacy, the levels of PGF2α and β EP, the uterine volume, the endometrial thickness, the menstrual volume, the dysmenorrhea degree, and the incidence of complications of the patients were compared between the two groups. Results: The total effective rate (94.3%) of the patients in the experimental group after treatment was significantly higher than that (78.9%) of the patients in the control group (P<0.05). The serum PGF 2a level of the patients in both groups after treatment had decreased significantly, and which (197.64±35.62 pg/ml) of the patients in the experimental group was significantly lower than that (287.59±56.38 pg/ml) of the patients in the control group. The β EP level of the patients in both groups after treatment had increased significantly, and which (189.95±25.14 ng/L) of the patients in the experimental group was significantly lower than that (160.25±22.94 ng/L) of the patients in the control group. The uterine volume and the endometrial thickness of the patients in both groups after treatment had decreased significantly, and which (131.84±7.24cm3 and 8.30±1.21mm) of the patients in the experimental group were significantly lower than those (154.68±5.94cm3 and 9.56±1.07mm) of the patients in the control group. The menstrual volume and the dysmenorrhea score of the patients in both groups after treatment had decreased significantly, and which (51.52±5.97ml and 1.14±0.28 points) of the patients in the experimental group were significantly lower than those (68.64±6.63ml and 2.29±0.44 points) of the patients in the control group (all P<0.05). The main complications of the patients in the two groups were dizziness, nausea, abdominal pain, and breast pain. The total incidence of the complications (5.7%) of the patients in the experimental group had no significantly different from that (13.5%) of the patients in the control group (P＞0.05). Conclusion: Mifepristone combined with getrienone for treating the patients with adenomyosis can improve the therapeutic efficacy, and which may related with the effectively increase of the PGF2α and β EP levels and the uterine recovery of the patients.
|
|
|
|
|
|
|
|
|
